ABSTRACT OBJECTIVE: In the ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials, the adjuvanted recombinant zoster vaccine (RZV) demonstrated ≥90% efficacy in preventing herpes zoster (HZ) in all age groups ≥50 years. Given the increased HZ risk associated with certain underlying autoimmune diseases or their treatment regimes, we conducted a post hoc analysis of RZV's efficacy against HZ and safety profile [specifically, the occurrence of serious adverse events (SAEs)] in ZOE-50/70 participants who reported pre-existing potential immune-mediated diseases (pIMDs) at enrolment and were not on immunosuppressive therapies. METHODS:Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomized to receive two doses of RZV or placebo 2 months apart. In this subgroup analysis of participants with at least one pIMD at enrolment, the efficacy was calculated for two-dose recipients who did not develop confirmed HZ before 30 days post-dose 2. SAE occurrence was evaluated for all participants who received at least one dose. RESULTS: Of the 14 645 RZV and 14 660 placebo recipients from the ZOE-50/70 studies, 983 and 960, respectively, reported at least one pre-existing pIMD at enrolment and were included in these analyses. The most frequent pre-existing conditions were psoriasis, spondyloarthropathy and RA. Efficacy against HZ was 90.5% (95% CI: 73.5, 97.5%) overall with the lowest being 84.4% (95% CI: 30.8, 98.3%) in the 70-79-year-old age group. SAEs and fatal SAEs were similar between RZV and placebo recipients. CONCLUSION: In ZOE-50/70 participants with pre-existing pIMDs, RZV was highly efficacious against HZ and SAE incidence was similar between RZV and placebo recipients. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT01165177 (ZOE-50), NCT01165229 (ZOE-70).
RCT Entities:
ABSTRACT OBJECTIVE: In the ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials, the adjuvanted recombinant zoster vaccine (RZV) demonstrated ≥90% efficacy in preventing herpes zoster (HZ) in all age groups ≥50 years. Given the increased HZ risk associated with certain underlying autoimmune diseases or their treatment regimes, we conducted a post hoc analysis of RZV's efficacy against HZ and safety profile [specifically, the occurrence of serious adverse events (SAEs)] in ZOE-50/70 participants who reported pre-existing potential immune-mediated diseases (pIMDs) at enrolment and were not on immunosuppressive therapies. METHODS: Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomized to receive two doses of RZV or placebo 2 months apart. In this subgroup analysis of participants with at least one pIMD at enrolment, the efficacy was calculated for two-dose recipients who did not develop confirmed HZ before 30 days post-dose 2. SAE occurrence was evaluated for all participants who received at least one dose. RESULTS: Of the 14 645 RZV and 14 660 placebo recipients from the ZOE-50/70 studies, 983 and 960, respectively, reported at least one pre-existing pIMD at enrolment and were included in these analyses. The most frequent pre-existing conditions were psoriasis, spondyloarthropathy and RA. Efficacy against HZ was 90.5% (95% CI: 73.5, 97.5%) overall with the lowest being 84.4% (95% CI: 30.8, 98.3%) in the 70-79-year-old age group. SAEs and fatal SAEs were similar between RZV and placebo recipients. CONCLUSION: In ZOE-50/70 participants with pre-existing pIMDs, RZV was highly efficacious against HZ and SAE incidence was similar between RZV and placebo recipients. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT01165177 (ZOE-50), NCT01165229 (ZOE-70).
Authors: Marta López-Fauqued; Laura Campora; Frédérique Delannois; Mohamed El Idrissi; Lidia Oostvogels; Ferdinandus J De Looze; Javier Diez-Domingo; Thomas C Heineman; Himal Lal; Janet E McElhaney; Shelly A McNeil; Wilfred Yeo; Fernanda Tavares-Da-Silva Journal: Vaccine Date: 2019-03-29 Impact factor: 3.641
Authors: Emily Baumrin; Abby Van Voorhees; Amit Garg; Steven R Feldman; Joseph F Merola Journal: J Am Acad Dermatol Date: 2019-03-15 Impact factor: 11.527
Authors: Adriana Bastidas; Javier de la Serna; Mohamed El Idrissi; Lidia Oostvogels; Philippe Quittet; Javier López-Jiménez; Filiz Vural; David Pohlreich; Tsila Zuckerman; Nicolas C Issa; Gianluca Gaidano; Je-Jung Lee; Sunil Abhyankar; Carlos Solano; Jaime Perez de Oteyza; Michael J Satlin; Stefan Schwartz; Magda Campins; Alberto Rocci; Carlos Vallejo Llamas; Dong-Gun Lee; Sen Mui Tan; Anna M Johnston; Andrew Grigg; Michael J Boeckh; Laura Campora; Marta Lopez-Fauqued; Thomas C Heineman; Edward A Stadtmauer; Keith M Sullivan Journal: JAMA Date: 2019-07-09 Impact factor: 56.272
Authors: Alemnew F Dagnew; Osman Ilhan; Won-Sik Lee; Dariusz Woszczyk; Jae-Yong Kwak; Stella Bowcock; Sang Kyun Sohn; Gabriela Rodriguez Macías; Tzeon-Jye Chiou; Dimas Quiel; Mickael Aoun; Maria Belen Navarro Matilla; Javier de la Serna; Samuel Milliken; John Murphy; Shelly A McNeil; Bruno Salaun; Emmanuel Di Paolo; Laura Campora; Marta López-Fauqued; Mohamed El Idrissi; Anne Schuind; Thomas C Heineman; Peter Van den Steen; Lidia Oostvogels Journal: Lancet Infect Dis Date: 2019-08-06 Impact factor: 25.071
Authors: Himal Lal; Anthony L Cunningham; Olivier Godeaux; Roman Chlibek; Javier Diez-Domingo; Shinn-Jang Hwang; Myron J Levin; Janet E McElhaney; Airi Poder; Joan Puig-Barberà; Timo Vesikari; Daisuke Watanabe; Lily Weckx; Toufik Zahaf; Thomas C Heineman Journal: N Engl J Med Date: 2015-04-28 Impact factor: 91.245
Authors: Peter Vink; Josep Maria Ramon Torrell; Ana Sanchez Fructuoso; Sung-Joo Kim; Sang-Il Kim; Jeff Zaltzman; Fernanda Ortiz; Josep Maria Campistol Plana; Ana Maria Fernandez Rodriguez; Henar Rebollo Rodrigo; Magda Campins Marti; Rafael Perez; Francisco Manuel González Roncero; Deepali Kumar; Yang-Jen Chiang; Karen Doucette; Lissa Pipeleers; Maria Luisa Agüera Morales; Maria Luisa Rodriguez-Ferrero; Antonio Secchi; Shelly A McNeil; Laura Campora; Emmanuel Di Paolo; Mohamed El Idrissi; Marta López-Fauqued; Bruno Salaun; Thomas C Heineman; Lidia Oostvogels Journal: Clin Infect Dis Date: 2020-01-02 Impact factor: 9.079
Authors: Laura P Hurley; Sean T O'Leary; Kathleen Dooling; Tara C Anderson; Lori A Crane; Jessica R Cataldi; Michaela Brtnikova; Brenda L Beaty; Carol Gorman; Angela Guo; Megan C Lindley; Allison Kempe Journal: J Gen Intern Med Date: 2022-07-06 Impact factor: 6.473
Authors: Alemnew F Dagnew; Peter Vink; Mamadou Drame; David O Willer; Bruno Salaun; Anne E Schuind Journal: Hum Vaccin Immunother Date: 2021-06-30 Impact factor: 3.452